Health
Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch
Johnson & Johnson
JNJ,
-1.69%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine provided a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates, the company said. Based on the strength of the data, a Phase 1/2a first-i…
-
Business14 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News19 hours ago28 years later: Grim reality for single house hunters revealed
-
Noosa News14 hours agoDangerous driving charges, Maroochydore – Sunshine Coast
-
General22 hours agoRussia launches its biggest attack on Ukraine’s gas network since war began on the eve of winter